
ATAI Stock Forecast & Price Target
ATAI Analyst Ratings
Bulls say
ATAI Life Sciences NV exhibits a promising outlook due to its advancing pipeline of psychedelic-based therapies, specifically with BPL-003, which has demonstrated potential for durable treatment effects in alcohol use disorder (AUD). Recent data indicates that BPL-003 may achieve a significant and lasting impact on patient outcomes, as evidenced by half of the patients maintaining complete abstinence for up to 12 weeks post-treatment. Additionally, the favorable tolerance profile and sustained antidepressant effects observed in related studies bolster the company's position in the mental health treatment landscape, making it a noteworthy candidate for future investment consideration.
Bears say
ATAI Life Sciences NV is currently navigating a challenging financial landscape, with reported substantial operating losses that raise concerns about the sustainability of its business model. Furthermore, the company relies heavily on the success of its clinical trials and the potential market uptake of its psychedelic-based therapies, which remain speculative and uncertain given the evolving regulatory environment. Additionally, limited cash reserves may hinder ATAI's ability to fund its ongoing research and development initiatives, impacting its long-term growth prospects.
This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.
ATAI Analyst Forecast & Price Prediction
Start investing in ATAI
Order type
Buy in
Order amount
Est. shares
0 shares